CEO Liu Yujie of Jieke Life Unveils a New Era of Assisted Reproduction at the World Fertility Industry Alliance Summit

On April 26, 2024, Ms. Liu Yujie, Founder and CEO of Hainan Jieke Health Technology Co., Ltd. (Jieke Life), delivered an engaging keynote speech at the World Fertility Industry Alliance (WFA) Brand Summit, unveiling Jieke Life International Surrogacy Center—a facility established by the core team formerly behind a renowned Ukrainian surrogacy brand, dedicated to delivering efficient, lawful assisted reproduction services to infertility patients and healthcare institutions worldwide.

On April 26, 2024, Ms. Liu Yujie, Founder and CEO of Hainan Jieke Health Technology Co., Ltd. (Jieke Life), delivered an engaging keynote speech at the World Fertility Industry Alliance (WFA) Brand Summit, unveiling Jieke Life International Surrogacy Center. This center was established by the core team formerly behind a renowned Ukrainian surrogacy brand, with the mission of providing efficient, lawful assisted reproduction services to infertility patients and healthcare institutions worldwide.

Since its inception, Jieke Life International Surrogacy Center has consistently delivered legal reproductive services—including IVF surrogacy programs in Kyrgyzstan and premium egg freezing—to both individual (C-end) clients and institutional (B-end) healthcare providers. Its foundation rests on Founder Ms. Liu Yujie’s 7+ years of deep expertise in international surrogacy, complemented by a seasoned sales and operations team possessing specialized knowledge and exceptional service ethos.

News Details – Page Editor – Jianzhanbaohe

In her speech, Ms. Liu Yujie highlighted several key service advantages of Jieke Life. First, Kyrgyzstan’s Law on Protection of Citizens’ Health, which entered into force on January 12, 2024, explicitly affirms that all citizens—regardless of health status or marital status—have the right to pursue parenthood via IVF-based surrogacy, thereby establishing a fully compliant and legally robust environment for Jieke Life’s operations. Second, Kyrgyzstan’s comprehensive surrogacy packages offer comparatively low total costs, outstanding value-for-money, and seamless travel logistics—including safe entry and convenient transportation—greatly enhancing accessibility for domestic and international clients.

Moreover, Jieke Life leverages extensive surrogacy resources and vertically integrated industry advantages in Kyrgyzstan, enabling rapid recruitment of gestational carriers and timely completion of embryo transfer procedures. An average timeline of just three months from initiation to embryo transfer ranks among the fastest and most exceptional globally. Jieke Life’s cross-border teams—experienced across multiple countries and years—collaborate seamlessly with professional, focused medical coordination capabilities. Their clearly defined, highly controllable processes ensure efficient, high-quality execution and agile responsiveness to complex or unforeseen circumstances.

Ms. Liu Yujie stated that Jieke Life (Dreamkids) is committed to ‘Optimal Conception, Loving Futures’—empowering hopeful parenthood and co-creating new life. She expressed her aspiration for Jieke Life to become a trusted brand for clients and a true partner for collaborators—achieving mutual success and shared growth. She also voiced an open, collaborative vision for the future development of the assisted reproductive technology (ART) industry, grounded in mutual support and win-win outcomes.

This keynote not only showcased Jieke Life’s capabilities and competitive strengths but also significantly elevated its global brand image. As public awareness and concern around fertility challenges continue to rise, Jieke Life stands poised to bring renewed hope and meaningful solutions to countless individuals and couples facing infertility. [图片:https://cdn.yun.sooce.cn/6/59417/png/1747708899426449c2f74a22d0cf3e26ffa03a2c07963.png?version=1747708901][Jieke Life International Surrogacy Center official logo]

This article is a public-information summary published by WFA. It is intended for industry, media and the general public, and does not constitute medical or investment advice.